The United States Food and Drug Administration (FDA) has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said Friday, May 19. The therapy, epcoritamab, which will be sold under the brand name Epkinly, treats a type of advanced large B-cell lymphoma, a cancer that starts in white blood cells. It is the first-of-its-kind therapy to be approved by the FDA for the disease which annually affects 150,000 people globally.

https://technology.inquirer.net/124227/us-fda-approves-genmab-abbvies-blood-cancer-therapy

#inquirer